The 20 references in paper A. Vizel' A., I. Vizel' Yu., А. Визель А., И. Визель Ю. (2015) “От качественной спирометрии к оптимальной бронхолитической терапии (аналитический обзор) // From high-quality spirometry to optimal bronchodilator therapy (analytical review)” / spz:neicon:pulmonology:y:2015:i:3:p:368-372

1
Miller M.R., Hankinson J., Brusasco V. et al. ATS / ERS Task Force. Standardisation of spirometry. Eur. Respir. J.2005; 26 (2): 319–338.
(check this in PDF content)
2
Müller-Brandes C., Krämer U., Gappa M. et al. LUNOKID: can numerical American Thoracic Society / European Respiratory Society quality criteria replace visual inspection of spirometry? Eur. Respir. J. 2014; 43 (5): 1347–1356.
(check this in PDF content)
3
Satake M., Shioya T., Uemura S. et al. Dynamic hyperinflation and dyspnea during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. Int. J. Chron. Obstruct. Pulm. Dis.2015; 10: 153–158.
(check this in PDF content)
4
Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies: ERS / ISAM Task force report. Eur. Respir. J. 2011; 37 (6): 1308–1331.
(check this in PDF content)
5
Sheth P., Stein S.W., Myrdal P.B. Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers.AAPS PharmSciTech.2015; 16 (1): 192–201.
(check this in PDF content)
6
Oliveira P.D., Menezes A.M., Bertoldi A.D. et al. Assessment of inhaler techniques employed by patients with respiratory diseases in southern Brazil: a population-based study. J. Bras. Pneumol. 2014; 40 (5): 513–520.
(check this in PDF content)
7
Ganguly A., Das A.K., Roy A. et al. Study of proper use of inhalational devices by bronchial asthma or COPD patients attending a tertiary care hospital.J. Clin. Diagn. Res. 2014;
(check this in PDF content)
8
10): HC04–07. 8. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug. Deliv. Rev. 2014; 75: 18–31.
(check this in PDF content)
9
Sliwiński P., Chazan R., D-browiecki P. et al. Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD. Pneumonol. Alergol. Pol. 2014; 8 2(3): 300–310.
(check this in PDF content)
10
Du P., Du J., Smyth H.D. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size. AAPS PharmSciTech. 2014; 15 (6): 1417–1428.
(check this in PDF content)
11
Mehta R., Daley-Yates P.T., Jenkins K. et al. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler. Pulm. Pharmacol. Ther. 2014; 29 (1): 66–73.
(check this in PDF content)
12
Azouz W., Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim. Care Respir. J.2012; 21 (2): 208–213.
(check this in PDF content)
13
Kanabuchi K., Kondo T., Tanigaki T. et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J. Exp. Clin. Med. 2011; 36 (1): 1–4.
(check this in PDF content)
14
Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.
(check this in PDF content)
15
Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.Int. J. Chron. Obstruct. Pulm. Dis.2011; 6: 353–363.
(check this in PDF content)
16
Kondo T., Tanigaki T., Hibino M. et al. Resistances of dry powder inhalers and training whistles and their clinical significance. Arerugi. 2014; 63 (10): 1325–1329.
(check this in PDF content)
17
Weers J.G., Clark A.R., Rao N. et al. In vitro-in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler®. Aerosol. Med. Pulm. Drug Deliv.2014, Dec. 17 [Epub ahead of print].
(check this in PDF content)
18
Molimard M., Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J. Aerosol. Med. Pulm. Drug Deliv.2015; 28 (3): 219–228.
(check this in PDF content)
19
Frampton J.E. QVA149 (indacaterol / glycopyrronium fixeddose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488.
(check this in PDF content)
20
Prakash A., Babu K.S., Morjaria J.B. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.Int. J. Chron. Obstruct. Pulm. Dis.2015; 10: 111–123. Поступила 01.06.15
(check this in PDF content)